A new standardized framework proposed by researchers in the CRO sector targets a recurring operational failure: study-specific subject ID conventions that fragment tracking across sponsor portfolios and extension studies. The authors argue that non-uniform IDs increase duplication risk, weaken continuity for rescreened participants, and complicate downstream regulatory review. The proposed schema uses structured components—site number, program identifier, study phase number, and sequence identifiers—so that subject IDs remain traceable across trials while staying compatible with FDA expectations and CDISC submission needs. The paper explicitly ties the operational problem to data integrity and review efficiency. For sponsors and CROs, adoption could reduce rescreening complexity, improve data lineage, and lower the chance that audit or reconciliation efforts slow regulatory submissions. It also reflects a broader push toward harmonization in trial operations as clinical programs become more decentralized and data-heavy.